{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:58Z","timestamp":1792725238542,"version":"4.5.0"},"reference-count":144,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bbagrm.2020.194564","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T20:03:58Z","timestamp":1588536238000},"page":"194564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["MLL-rearranged infant leukaemia: A \u2018thorn in the side\u2019 of a remarkable success story"],"prefix":"10.1016","volume":"1863","author":[{"given":"Siobhan","family":"Rice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.bbagrm.2020.194564_bb0010","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.bbagrm.2020.194564_bb0015","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.bbagrm.2020.194564_bb0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"9583","key":"10.1016\/j.bbagrm.2020.194564_bb0030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pbc.25322","article-title":"Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3)","volume":"62","author":"Dreyer","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0040","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/leu.2010.284","article-title":"Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement","volume":"25","author":"Bueno","year":"2011","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.bbagrm.2020.194564_bb0045","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1182\/blood-2015-09-667378","article-title":"Revisiting the biology of infant t(4;11)\/MLL-AF4+ B-cell acute lymphoblastic leukemia","volume":"126","author":"Sanjuan-Pla","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1101\/gad.1195504","article-title":"Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis","volume":"18","author":"Daser","year":"2004","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2141.2010.08459.x","article-title":"Mechanisms of leukemogenesis by MLL fusion proteins","volume":"152","author":"Marschalek","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"16","key":"10.1016\/j.bbagrm.2020.194564_bb0060","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood-2016-10-691428","article-title":"Mouse models of MLL leukemia: recapitulating the human disease","volume":"129","author":"Milne","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2018-04-785980","article-title":"How I treat infant leukemia","volume":"133","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2020.194564_bb0070","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.canlet.2019.11.005","article-title":"KMT2A rearranged acute lymphoblastic leukaemia: unravelling the genomic complexity and heterogeneity of this high-risk disease","volume":"469","author":"Forgione","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbagrm.2020.194564_bb0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-rearranged leukemias-an update on science and clinical approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front. Pediatr."},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0080","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2011.267","article-title":"Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report","volume":"26","author":"Creutzig","year":"2012","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.bbagrm.2020.194564_bb0085","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V98.13.3589","article-title":"Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group","volume":"98","author":"Kawasaki","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0090","first-page":"157","article-title":"US cancer incidence and mortality in the first year of life","volume":"133","author":"Bader","year":"1979","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.bbagrm.2020.194564_bb0095","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/asheducation-2013.1.596","article-title":"Treatment of infant leukemias: challenge and promise","volume":"2013","author":"Brown","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjh.15246","article-title":"Neonatal leukaemia","volume":"182","author":"Roberts","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"7 Suppl","key":"10.1016\/j.bbagrm.2020.194564_bb0105","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/pbc.21352","article-title":"Acute lymphoblastic leukemia in infancy","volume":"49","author":"Silverman","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2005-07-3011","article-title":"Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group","volume":"108","author":"Hilden","year":"2006","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bbagrm.2020.194564_bb0115","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbagrm.2020.194564_bb0120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0125","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.leu.2404578","article-title":"Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement","volume":"21","author":"Jansen","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0135","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.V87.3.1134.bloodjournal8731134","article-title":"Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements","volume":"87","author":"Behm","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbagrm.2020.194564_bb0140","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.leukres.2011.03.015","article-title":"Expression of NG2 antigen in MLL-rearranged acute leukemias: how complex does it get?","volume":"35","author":"Menendez","year":"2011","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0145","first-page":"154","article-title":"Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping","volume":"86","author":"Wuchter","year":"2001","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0150","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2017.294","article-title":"NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL","volume":"32","author":"Prieto","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0155","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.leu.2403253","article-title":"In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype","volume":"18","author":"Ramakers-van Woerden","year":"2004","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.bbagrm.2020.194564_bb0160","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2010-03-273532","article-title":"Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study","volume":"116","author":"Mann","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bbagrm.2020.194564_bb0165","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2020.194564_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbagrm.2020.194564_bb0175","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.25953","article-title":"Lineage switch in MLL-rearranged infant Leukemia following CD19-directed therapy","volume":"63","author":"Rayes","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0180","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23266","article-title":"Lineage switch in childhood acute leukemia: an unusual event with poor outcome","volume":"87","author":"Rossi","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0185","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/sj.leu.2402595","article-title":"Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases","volume":"16","author":"Borkhardt","year":"2002","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bbagrm.2020.194564_bb0190","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/leu.2009.17","article-title":"Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol","volume":"23","author":"Van der Velden","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bbagrm.2020.194564_bb0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0200","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2003-07-2441","article-title":"FLT3 mutations in childhood acute lymphoblastic leukemia","volume":"103","author":"Armstrong","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbagrm.2020.194564_bb0205","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1038\/leu.2012.161","article-title":"Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia","volume":"26","author":"Chillon","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bbagrm.2020.194564_bb0210","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","article-title":"Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia","volume":"106","author":"Stam","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0215","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","article-title":"FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression","volume":"105","author":"Brown","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbagrm.2020.194564_bb0220","series-title":"Pediatric Blood & Cancer","article-title":"Addition of FLT3 inhibitor lestaurtinib to post-induction chemotherapy does not improve outcomes in MLL-rearranged infant acute lymphoblastic leukemia (ALL): AALL0631, a Children's Oncology Group study","year":"2016"},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0225","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbagrm.2020.194564_bb0230","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.bbagrm.2020.194564_bb0235","doi-asserted-by":"crossref","first-page":"11367","DOI":"10.1158\/0008-5472.CAN-05-1041","article-title":"Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications","volume":"65","author":"Milne","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbagrm.2020.194564_bb0240","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/hmg\/ddl444","article-title":"The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling","volume":"16","author":"Bitoun","year":"2007","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.bbagrm.2020.194564_bb0245","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2008.10.001","article-title":"H3K79 methylation profiles define murine and human MLL-AF4 leukemias","volume":"14","author":"Krivtsov","year":"2008","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0250","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MOH.0000000000000123","article-title":"Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L","volume":"22","author":"Stein","year":"2015","journal-title":"Curr. Opin. Hematol."},{"issue":"22","key":"10.1016\/j.bbagrm.2020.194564_bb0255","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V128.22.2780.2780","article-title":"Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute Leukemia","volume":"128","author":"Shukla","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bbagrm.2020.194564_bb0260","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.V124.21.387.387","article-title":"The DOT1L inhibitor EPZ-5676: safety and activity in relapsed\/refractory patients with MLL-rearranged Leukemia","volume":"124","author":"Stein","year":"2014","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bbagrm.2020.194564_bb0265","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.bbagrm.2020.194564_bb0270","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","article-title":"Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options","volume":"114","author":"Stumpel","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bbagrm.2020.194564_bb0275","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/blood-2009-09-243634","article-title":"Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting","volume":"115","author":"Schafer","year":"2010","journal-title":"Blood"},{"issue":"7370","key":"10.1016\/j.bbagrm.2020.194564_bb0280","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.bbagrm.2020.194564_bb0285","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1158\/0008-5472.CAN-15-0236","article-title":"Generation of a selective small molecule inhibitor of the CBP\/p300 bromodomain for leukemia therapy","volume":"75","author":"Picaud","year":"2015","journal-title":"Cancer Res."},{"issue":"7370","key":"10.1016\/j.bbagrm.2020.194564_bb0290","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbagrm.2020.194564_bb0295","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/leu.2016.165","article-title":"Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin","volume":"31","author":"Cruickshank","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0300","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"issue":"21","key":"10.1016\/j.bbagrm.2020.194564_bb0305","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1182\/blood.V124.21.3650.3650","article-title":"Invasive Candida infections in pediatric patients treated on the pilot study of decitabine and vorinostat with chemotherapy for relapsed ALL: a report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium","volume":"124","author":"Burke","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0310","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccr.2014.03.008","article-title":"Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4","volume":"25","author":"Liu","year":"2014","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.bbagrm.2020.194564_bb0315","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V124.21.972.972","article-title":"Targeted inhibition of the MLL transcriptional complex by proteosome inhibitors elicits a high response rate in relapsed\/refractory MLL rearranged leukemia","volume":"124","author":"Koss","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0320","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","article-title":"Survival after blinatumomab treatment in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J"},{"issue":"18","key":"10.1016\/j.bbagrm.2020.194564_bb0325","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0330","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bbagrm.2020.194564_bb0335","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","volume":"7","author":"Mejstrikova","year":"2017","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.bbagrm.2020.194564_bb0340","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2017-02-749101","article-title":"Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia","volume":"130","author":"Wayne","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0345","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1470-2045(12)70010-4","article-title":"Anti-CD22 therapy in acute lymphoblastic leukaemia","volume":"13","author":"Hoelzer","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bbagrm.2020.194564_bb0350","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.bbagrm.2020.194564_bb0355","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bbagrm.2020.194564_bb0360","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"issue":"9967","key":"10.1016\/j.bbagrm.2020.194564_bb0365","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.bbagrm.2020.194564_bb0370","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbagrm.2020.194564_bb0375","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0380","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"issue":"374","key":"10.1016\/j.bbagrm.2020.194564_bb0385","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0390","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-018-0212-z","article-title":"TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells","volume":"32","author":"Li","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bbagrm.2020.194564_bb0395","article-title":"H3K79me2\/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1\/CD133 in MLL-AF4 leukemia cells","author":"Godfrey","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bbagrm.2020.194564_bb0400","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/s41375-019-0418-8","article-title":"CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity","volume":"33","author":"Bueno","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bbagrm.2020.194564_bb0405","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.bbagrm.2020.194564_bb0410","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41375-018-0353-0","article-title":"NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia","volume":"33","author":"Lopez-Millan","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0415","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.leu.2404577","article-title":"Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: the 'big sister' of the infant disease?","volume":"21","author":"Mann","year":"2007","journal-title":"Leukemia"},{"issue":"9321","key":"10.1016\/j.bbagrm.2020.194564_bb0420","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(02)08782-2","article-title":"Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region","volume":"359","author":"Pui","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bbagrm.2020.194564_bb0425","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/leu.2014.142","article-title":"A revised definition for cure of childhood acute lymphoblastic leukemia","volume":"28","author":"Pui","year":"2014","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.bbagrm.2020.194564_bb0430","doi-asserted-by":"crossref","first-page":"13950","DOI":"10.1073\/pnas.94.25.13950","article-title":"Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots","volume":"94","author":"Gale","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0435","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjh.13613","article-title":"Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia","volume":"171","author":"Mansur","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.bbagrm.2020.194564_bb0440","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-12-3817","article-title":"Leukemia in twins: lessons in natural history","volume":"102","author":"Greaves","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0445","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrc1164","article-title":"Origins of chromosome translocations in childhood leukaemia","volume":"3","author":"Greaves","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"6427","key":"10.1016\/j.bbagrm.2020.194564_bb0450","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/363358a0","article-title":"In utero rearrangements in the trithorax-related oncogene in infant leukaemias","volume":"363","author":"Ford","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbagrm.2020.194564_bb0455","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.earlhumdev.2004.10.004","article-title":"In utero origins of childhood leukaemia","volume":"81","author":"Greaves","year":"2005","journal-title":"Early Hum. Dev."},{"issue":"8","key":"10.1016\/j.bbagrm.2020.194564_bb0460","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-018-0015-6","article-title":"A causal mechanism for childhood acute lymphoblastic leukaemia","volume":"18","author":"Greaves","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"7137","key":"10.1016\/j.bbagrm.2020.194564_bb0465","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"issue":"9189","key":"10.1016\/j.bbagrm.2020.194564_bb0470","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(99)09403-9","article-title":"Prenatal origin of acute lymphoblastic leukaemia in children","volume":"354","author":"Wiemels","year":"1999","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.bbagrm.2020.194564_bb0475","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1073\/pnas.1221099110","article-title":"Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia","volume":"110","author":"Ma","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0480","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bbagrm.2020.194564_bb0485","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2018.206375","article-title":"Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis","volume":"104","author":"Agraz-Doblas","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bbagrm.2020.194564_bb0490","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/gcc.22090","article-title":"The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia","volume":"52","author":"Dobbins","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0495","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.178.3.787","article-title":"Ontogeny-related changes in proliferative potential of human hematopoietic cells","volume":"178","author":"Lansdorp","year":"1993","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.bbagrm.2020.194564_bb0500","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1182\/blood.V83.11.3170.3170","article-title":"Expression of CD33, CD38, and HLA-DR on CD34+ human fetal liver progenitors with a high proliferative potential","volume":"83","author":"Muench","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0505","first-page":"293","article-title":"Relative to adult marrow, fetal liver repopulates nearly five times more effectively long-term than short-term","volume":"25","author":"Harrison","year":"1997","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.bbagrm.2020.194564_bb0510","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood.V94.8.2686.420k15_2686_2695","article-title":"Unique differentiation programs of human fetal liver stem cells shown both in vitro and in vivo in NOD\/SCID mice","volume":"94","author":"Nicolini","year":"1999","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0515","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0301-472X(99)00078-8","article-title":"Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow","volume":"27","author":"Holyoake","year":"1999","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0520","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/scd.2016.0083","article-title":"Comparison of human hematopoietic reconstitution in different strains of immunodeficient mice","volume":"26","author":"Beyer","year":"2017","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.bbagrm.2020.194564_bb0525","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/nyas.12769","article-title":"A developmental switch between fetal and adult B lymphopoiesis","volume":"1362","author":"Li","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.bbagrm.2020.194564_bb0530","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1189\/jlb.0113048","article-title":"The human fetal lymphocyte lineage: identification by CD27 and LIN28B expression in B cell progenitors","volume":"94","author":"McWilliams","year":"2013","journal-title":"J. Leukoc. Biol."},{"issue":"6073","key":"10.1016\/j.bbagrm.2020.194564_bb0535","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1126\/science.1216557","article-title":"Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis","volume":"335","author":"Yuan","year":"2012","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bbagrm.2020.194564_bb0540","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/ncb2783","article-title":"The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells","volume":"15","author":"Copley","year":"2013","journal-title":"Nat. Cell Biol."},{"issue":"7","key":"10.1016\/j.bbagrm.2020.194564_bb0545","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ng.392","article-title":"Lin28 promotes transformation and is associated with advanced human malignancies","volume":"41","author":"Viswanathan","year":"2009","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.bbagrm.2020.194564_bb0550","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.biocel.2013.02.006","article-title":"LIN28\/LIN28B: an emerging oncogenic driver in cancer stem cells","volume":"45","author":"Zhou","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0555","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2002-03-0896","article-title":"B lymphopoiesis is active throughout human life, but there are developmental age-related changes","volume":"101","author":"Rossi","year":"2003","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bbagrm.2020.194564_bb0560","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood.2019001289","article-title":"Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs","volume":"134","author":"O'Byrne","year":"2019","journal-title":"Blood"},{"issue":"6269","key":"10.1016\/j.bbagrm.2020.194564_bb0565","doi-asserted-by":"crossref","first-page":"aab2116","DOI":"10.1126\/science.aab2116","article-title":"Distinct routes of lineage development reshape the human blood hierarchy across ontogeny","volume":"351","author":"Notta","year":"2016","journal-title":"Science"},{"issue":"S1","key":"10.1016\/j.bbagrm.2020.194564_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000060","volume":"2","year":"2018","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0575","first-page":"407","article-title":"Development of pre-B and B lymphocytes in the human fetus","volume":"56","author":"Asma","year":"1984","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.bbagrm.2020.194564_bb0580","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4049\/jimmunol.156.2.866","article-title":"B cells are generated throughout life in humans","volume":"156","author":"Nunez","year":"1996","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.bbagrm.2020.194564_bb0585","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.3324\/haematol.2018.191718","article-title":"The fetal liver lymphoid-primed multipotent progenitor provides the prerequisites for the initiation of t(4;11) MLL-AF4 infant leukemia","volume":"103","author":"Malouf","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bbagrm.2020.194564_bb0590","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/leu.2014.154","article-title":"Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement","volume":"29","author":"Bardini","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bbagrm.2020.194564_bb0595","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nm1253","article-title":"Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia","volume":"11","author":"Castor","year":"2005","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0600","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/0008-5472.CAN-04-1356","article-title":"Leukemic stem cells in childhood high-risk ALL\/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells","volume":"65","author":"Hotfilder","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbagrm.2020.194564_bb0605","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ccr.2008.05.015","article-title":"In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties","volume":"14","author":"le Viseur","year":"2008","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.bbagrm.2020.194564_bb0610","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1084\/jem.20091050","article-title":"Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene","volume":"206","author":"Menendez","year":"2009","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.bbagrm.2020.194564_bb0615","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3324\/haematol.2018.202044","article-title":"Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions","volume":"104","author":"Bueno","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bbagrm.2020.194564_bb0620","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2012.4","article-title":"A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification","volume":"22","author":"Bueno","year":"2012","journal-title":"Cell Res."},{"issue":"7","key":"10.1016\/j.bbagrm.2020.194564_bb0625","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2017-04-777185","article-title":"The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment","volume":"130","author":"Lin","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0630","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.immuni.2017.09.009","article-title":"Molecular and functional characterization of lymphoid progenitor subsets reveals a bipartite architecture of human lymphopoiesis","volume":"47","author":"Alhaj Hussen","year":"2017","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0635","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.devcel.2017.12.005","article-title":"A human IPS model implicates embryonic B-myeloid fate restriction as developmental susceptibility to B acute lymphoblastic leukemia-associated ETV6-RUNX1","volume":"44","author":"Boiers","year":"2018","journal-title":"Dev. Cell"},{"issue":"43","key":"10.1016\/j.bbagrm.2020.194564_bb0640","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1073\/pnas.1211405109","article-title":"Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21","volume":"109","author":"Roy","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0645","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood-2002-07-2244","article-title":"Human cord blood CD34+Pax-5+ B-cell progenitors: single-cell analyses of their gene expression profiles","volume":"101","author":"Sanz","year":"2003","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.bbagrm.2020.194564_bb0650","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1073\/pnas.0907942107","article-title":"Ordering human CD34+CD10-CD19+ pre\/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways","volume":"107","author":"Sanz","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bbagrm.2020.194564_bb0655","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/bloodadvances.2018018093","article-title":"Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL","volume":"2","author":"Wolfl","year":"2018","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.bbagrm.2020.194564_bb0660","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1182\/blood-2010-12-322230","article-title":"Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia","volume":"117","author":"Montes","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0665","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2013.346","article-title":"Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize\/transform cord blood CD34+ cells","volume":"28","author":"Montes","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bbagrm.2020.194564_bb0670","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/0008-5472.CAN-15-2769","article-title":"Activated KRAS cooperates with MLL-AF4 to promote extramedullary engraftment and migration of cord blood CD34+ HSPC but is insufficient to initiate leukemia","volume":"76","author":"Prieto","year":"2016","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.bbagrm.2020.194564_bb0675","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/blood-2012-11-470146","article-title":"FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs","volume":"121","author":"Bueno","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0680","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccr.2006.08.020","article-title":"Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia","volume":"10","author":"Somervaille","year":"2006","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0685","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/leu.2012.363","article-title":"Cell of origin determines clinically relevant subtypes of MLL-rearranged AML","volume":"27","author":"Krivtsov","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bbagrm.2020.194564_bb0690","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2010-11-317529","article-title":"Modeling human infant MLL leukemia in mice: leukemia from fetal liver differs from that originating in postnatal marrow","volume":"117","author":"Chen","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbagrm.2020.194564_bb0695","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/leu.2012.343","article-title":"MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny","volume":"27","author":"Horton","year":"2013","journal-title":"Leukemia"},{"issue":"5824","key":"10.1016\/j.bbagrm.2020.194564_bb0700","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1139851","article-title":"Modeling the initiation and progression of human acute leukemia in mice","volume":"316","author":"Barabe","year":"2007","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bbagrm.2020.194564_bb0705","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/s41375-019-0465-1","article-title":"FLT3(N676K) drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis","volume":"33","author":"Hyrenius-Wittsten","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bbagrm.2020.194564_bb0710","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2016.10.008","article-title":"Instructive role of MLL-fusion proteins revealed by a model of t(4;11) pro-B acute lymphoblastic leukemia","volume":"30","author":"Lin","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbagrm.2020.194564_bb0715","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.celrep.2016.06.046","article-title":"Mll-AF4 confers enhanced self-renewal and lymphoid potential during a restricted window in development","volume":"16","author":"Barrett","year":"2016","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bbagrm.2020.194564_bb0720","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1084\/jem.20181765","article-title":"The developmental stage of the hematopoietic niche regulates lineage in MLL-rearranged leukemia","volume":"216","author":"Rowe","year":"2019","journal-title":"J. Exp. Med."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874939919303153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874939919303153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:28:16Z","timestamp":1761744496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874939919303153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":144,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1874939919303153"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagrm.2020.194564","relation":{},"ISSN":["1874-9399"],"issn-type":[{"value":"1874-9399","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MLL-rearranged infant leukaemia: A \u2018thorn in the side\u2019 of a remarkable success story","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagrm.2020.194564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"194564"}}